治疗前[99mTc]TcMAA SPECT/CT多分区剂量学在肝细胞癌90Y玻璃微球治疗计划中的应用:解剖分割与[99mTc]TcMAA分割的比较
纳入209例接受90Y玻璃微球治疗的肝细胞癌患者,回顾性比较解剖分割与[99mTc]TcMAA阈值分割对肿瘤及正常组织区的划分。解剖分割得到的灌注肿瘤和正常组织体积更大、吸收剂量更低;两种分割下总灌注肿瘤吸收剂量(TAD)每增加100 Gy均与客观缓解率(ORR)升高及总生存期(OS)改善相关。结论认为真实世界数据支持治疗前用[99mTc]TcMAA显像估算吸收剂量,两种分割方法均适用于治疗计划。
要点
- 解剖分割较[99mTc]TcMAA阈值分割所得灌注肿瘤和正常组织体积更大、吸收剂量更低。
- 两种分割下总灌注TAD每增加100 Gy,ORR的OR分别为1.22(95%CI 1.01-1.49;p=0.044)与1.19(95%CI 1.04-1.37;p=0.012)。
- 总灌注TAD每增加100 Gy,OS的HR分别为0.826(95%CI 0.714-0.954;p=0.009)与0.847(95%CI 0.765-0.936;p=0.001)。
核心结论
- 真实世界数据支持在90Y玻璃微球治疗肝细胞癌前用[99mTc]TcMAA显像估算吸收剂量,解剖分割与[99mTc]TcMAA阈值分割两种方法均适用于治疗计划。
研究设计与样本
- 纳入209例接受90Y玻璃微球治疗的肝细胞癌患者,要求至少1个肿瘤、直径≥3 cm且治疗前有[99mTc]TcMAA SPECT/CT显像。
- 回顾性使用专用剂量学软件进行分割:解剖分割(基于诊断CT/MRI)和[99mTc]TcMAA阈值分割(使用活性等轮廓阈值),CT/MRI与[99mTc]TcMAA SPECT/CT共配准。
- 用Logistic回归和Cox回归分别评估总灌注肿瘤吸收剂量(TAD)与客观缓解率(ORR)及总生存期(OS)的关系。
- 在亚组分析中用Bland-Altman分析和Pearson相关系数比较治疗前与治疗后剂量学。
主要发现
- 解剖分割较[99mTc]TcMAA阈值分割所得总灌注肿瘤和正常组织体积更大,导致吸收剂量更低。
- mRECIST ORR随总灌注TAD升高而升高:解剖分割每增加100 Gy的OR为1.22(95%CI 1.01-1.49;p=0.044),[99mTc]TcMAA阈值分割为1.19(95%CI 1.04-1.37;p=0.012)。
- 较高总灌注TAD与OS改善相关:解剖分割每增加100 Gy的HR为0.826(95%CI 0.714-0.954;p=0.009),[99mTc]TcMAA阈值分割为0.847(95%CI 0.765-0.936;p=0.001)。
- 治疗前与治疗后剂量学比较中,总灌注TAD的平均偏差为+11.5 Gy(95%一致性界限:-227.0至250.0),呈强正相关(Pearson相关系数=0.80)。
关键数值与推荐
- mRECIST ORR与总灌注TAD的Logistic回归:解剖分割OR 1.22(95%CI 1.01-1.49;p=0.044),[99mTc]TcMAA阈值分割OR 1.19(95%CI 1.04-1.37;p=0.012),均为每100 Gy TAD增加。
- OS与总灌注TAD的Cox回归:解剖分割HR 0.826(95%CI 0.714-0.954;p=0.009),[99mTc]TcMAA阈值分割HR 0.847(95%CI 0.765-0.936;p=0.001),均为每100 Gy TAD增加。
- 治疗前与治疗后总灌注TAD比较:平均偏差+11.5 Gy(95%一致性界限-227.0至250.0),Pearson相关系数=0.80。
临床怎么用
- 真实世界数据支持在90Y玻璃微球治疗肝细胞癌前使用[99mTc]TcMAA SPECT/CT估算吸收剂量,解剖分割与[99mTc]TcMAA阈值分割两种方法均适用于治疗计划。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pre-treatment [99mTc]TcMAA-based radioembolization treatment planning using multicompartment dosimetry involves the definition of the tumor and normal tissue compartments and calculation of the prescribed absorbed doses. The aim was to compare the real-world utility of anatomic and [99mTc]TcMAA-based segmentation of tumor and normal tissue compartments. MATERIALS AND METHODS: Included patients had HCC treated by glass [90Y]yttrium microspheres, ≥ 1 tumor, ≥ 3 cm diameter and [99mTc]TcMAA SPECT/CT imaging before treatment. Segmentation was performed retrospectively using dedicated dosimetry software: (1) anatomic (diagnostic CT/MRI-based), and (2) [99mTc]TcMAA threshold-based (i.e., using an activity-isocontour threshold). CT/MRI was co-registered with [99mTc]TcMAA SPECT/CT. Logistic regression and Cox regression, respectively, were used to evaluate relationships between total perfused tumor absorbed dose (TAD) and objective response rate (ORR) and overall survival (OS). In a subset-analysis pre- and post-treatment dosimetry were compared using Bland-Altman analysis and Pearson's correlation coefficient. RESULTS: A total of 209 patients were enrolled. Total perfused tumor and normal tissue volumes were larger when using anatomic versus [99mTc]TcMAA threshold segmentation, resulting in lower absorbed doses. mRECIST ORR was higher with increasing total perfused TAD (odds ratio per 100 Gy TAD increase was 1.22 (95% CI: 1.01-1.49; p = 0.044) for anatomic and 1.19 (95% CI: 1.04-1.37; p = 0.012) for [99mTc]TcMAA threshold segmentation. Higher total perfused TAD was associated with improved OS (hazard ratio per 100 Gy TAD increase was 0.826 (95% CI: 0.714-0.954; p = 0.009) and 0.847 (95% CI: 0.765-0.936; p = 0.001) for anatomic and [99mTc]TcMAA threshold segmentation, respectively). For pre- vs. post-treatment dosimetry comparison, the average bias for total perfused TAD was + 11.5 Gy (95% limits of agreement: -227.0 to 250.0) with a strong positive correlation (Pearson's correlation coefficient = 0.80). CONCLUSION: Real-world data support [99mTc]TcMAA imaging to estimate absorbed doses prior to treatment of HCC with glass [90Y]yttrium microspheres. Both anatomic and [99mTc]TcMAA threshold methods were suitable for treatment planning. TRIAL REGISTRATION NUMBER: NCT03295006.
引用
- Lam M, Garin E, Haste P, et al. Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation. Eur J Nucl Med Mol Imaging. 2024. PMID: 39331131. doi:10.1007/s00259-024-06920-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。